Amgen's immunology drug results —The Novo Nordisk Senate hearing —Sanofi's soul-searching Read on to learn more.

The board of directors for 23andMe quit following disagreements over the CEO's plans to privatize the DNA testing company.

SUNNYVALE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co., (Nasdaq: ME), a leading human genetics and preventive health ...

Personal information for nearly half of the popular genetic testing company's customers -- 6.9 million people -- were exposed ...

The pioneering DNA testing firm has been struggling to stay afloat financially despite ambitious ventures to provide health ...

All of 23andMe’s independent directors have resigned from its board in a rare move that marks the latest challenge for the ...

On Sept. 23, the board of directors at 23andMe, a prominent DNA testing company, announced their resignation following a series of disagreements with CEO Ann ...

Me's entire board of directors resigned over cofounder and CEO Anne Wojcicki's ongoing plan to take it private.

The history of the DNA-testing startup reads like a checklist of Silicon Valley clichés: founder squabbles, gobs of cash, a ...

Me has agreed to pay $30 million after a class action suit was brought against the company for last year's data breach.

Me Holding Co., (NASDAQ: ME) shares squeaked ahead mid-week Wednesday. The company, a leading human genetics and preventive health concern, today released a new report on the genetics of emotional ...

NEW YORK (AP) — All of 23andMe's independent directors resigned from its board this week, a rare move that marks the latest challenge for the genetic-testing company. The resignations follow ...